New CAR-T therapy targets Hard-to-Treat myeloma in early trial
NCT ID NCT04960579
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This early-stage study tests a new treatment called P-BCMA-ALLO1 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to attack cancer cells. The main goals are to check the safety of different doses and find the best dose to use in future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Advocate Aurora Health
Park Ridge, Illinois, 66068, United States
-
Blood Marrow and Transplant Group of Georgia
Atlanta, Georgia, 30342, United States
-
City of Hope
Goodyear, Arizona, 85338, United States
-
City of Hope
Chicago, Illinois, 60099, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute - Methodist Healthcare
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute - St. David's South Austin Medical Center
Austin, Texas, 78704, United States
-
University of California San Diego
San Diego, California, 92093, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-1350, United States
-
University of Oklahoma, Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4238, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Wayne State - Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.